Ciprofast 500
Broad Spectrum Antibiotic
  • Ciprofloxacin is a fluorinated-4-quinolone or fluoroquinolone antibacterial with a wider spectrum of activity than nalidixic acid and more favourable pharmacokinetics for use in systemic infection.
  • Ciprofloxacin is rapidly and well absorbed from the gastrointestinal tract. Oral bioavailability is approximately 70% and a peak plasma concentration of about 2.5 μg/ml is achieved 1 to 2 hours after a dose of 500 mg by mouth. Absorption may be delayed by the presence of food but not substantially affected  overall,
  • the plasma half life is about 3.5 to 4.5 hours, but may be prolonged in severe renal failure.
  • Plasma protein binding ranges from 20 to 40%.
  • Ciprofloxacin is widely distributed in the body, it crosses the placenta and is distributed into breast milk, and high concentrations are achieved in bile.
  • Approximately 40 to 50% of an orally administered dose is excreted in urine as unchanged drug. 

Each film coated tablet Ciprofast®  250 contains:

  • Ciprofloxacin   250 mg  (as Ciprofloxacin   HCl )

Each film coated tablet Ciprofast®  500 contains:

  • Ciprofloxacin   500 mg  (as Ciprofloxacin   HCl )

Each film coated tablet Ciprofast®  750 contains:

  • Ciprofloxacin   750 mg  (as Ciprofloxacin   HCl )

Ciprofast® is indicated in the treatment of a wide range of infections including: 

  • Biliary tract infection.
  • Gastro enteritis (including diarrhoea, campylobacter enteritis, salmonella enteritis and shigellosis)
  • Meningitis, otitis media, peritonitis and Q fever.
  • Lower respiratory tract infections.
  • Skin infections (including soft-tissue infections.)
  • Typhoid and paratyphoid fever.
  • Genito-urinary tract infections including gonorrhea.
  • Eye infections.
  • Oral and dental infections.
  • Bone and joint infections.

Ciprofast® is contraindicated in

  • patients with a history of hypersensitivity to Ciprofloxacin or other quinolone derivatives. 
  • Epileptics and patients with pre-existing CNS lesions. 
  • Children, adolescent, pregnant or breast-feeding mothers.  
  • Fluroquinolones are known to inhibit hepatic drug metabolism and may interfere with the clearance of drugs metabolized by the liver such as theophylline.
  • On the other hand, Cations like aluminum, magnesium, or iron reduce the absorption of Ciprofast® and related drugs when given concomitantly.
  • Ciprofast® should be used during pregnancy only if clearly needed. 
  • Ciprofast® is excreted in breast milk and should be used with caution in lactating mothers.

As with other quinolones, side effects are usually: 

  • Gastrointestinal disturbances include: nausea, vomiting, diarrhoea, abdominal pain and dyspepsia.
  • Headache, dizziness and restlessness are among the commonest effects on the CNS.
  • Hypersensitivity type reactions affecting the skin, in addition to rash and pruritus. 

¤ Ciprofast® should be taken with meals. Patients should maintain an adequate fluid intake during treatment, and avoid the concomitant use of aluminum and magnesium hydroxides.

  • The usual adult oral dose of Ciprofast® ranges from 250 to 750 mg twice daily depending on the severity and nature of the infection.
  • Single oral doses of 250 or 500 mg are used for the treatment of gonorrhoeae. 
  • A single oral dose of 500 mg is suggested for meningococcal meningitis prophylaxis.
  • Doses should be reduced in patients with severe renal impairment. Halving  the dose has been suggested when the creatinine clearance is less than 20 ml/minute or alternatively the dosage interval may be increased.

¤ Generally Ciprofast® should be continued for at least 2-days after the  signs and symptoms of infection have disappeared.

¤ Ciprofast®  should be used with caution in patients with

  • epilepsy
  • history of CNS disorders
  • and to those with impaired renal or hepaticfunctions
  • glucose-6-phosphate dehydrogenase deficiency 
  • diabetes.

¤ During treatment, patients should not expose themselves to sunlight, UV rays or sunray lamp (due to photosensitivity reactions.) 

¤ Avoid driving or other activities requiring alertness.

¤ Antacid or iron should not be taken within 2 hours of Ciprofast®.

  • Ciprofast® Film coated tablet 250 mg Blister of 10 Tablets, pack of one blister ).
  • Ciprofast® Film coated tablet 500 mg ( Blister of 10 Tablets, pack of one   blister ).
  • Ciprofast® Film coated tablet 750 mg ( Blister of 10 Tablets, pack of one blister ).
  • Store in a dry place at a temperature not exceeding 30° C.